| Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.Br J Ophthalmol | PMID 34656987PMC9985746 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer.Prostate Cancer Prostatic Dis | PMID 35790787无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.Allergy | PMID 35822924无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.Am J Kidney Dis | PMID 36058429无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Response to netakimab in radiographic axial spondyloarthritis patients with different baseline C-reactive protein, sacroiliitis evaluated by MRI and peripheral joint involvement status: a post-hoc analysis of the ASTERA study.Clin Exp Rheumatol | PMID 36062743无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.Arthritis Rheumatol | PMID 36066501无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study.Prostate Cancer Prostatic Dis | PMID 36097167无 PMCID | 2023-Mar | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.J Thorac Cardiovasc Surg | PMID 36137841无 PMCID | 2023-Mar | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.Prostate Cancer Prostatic Dis | PMID 36209239无 PMCID | 2023-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A phase 3, randomized, double-blind, placebo-controlled study evaluating a single, patient-initiated dose of amenamevir for recurrent herpes labialis.J Dermatol | PMID 36353762无 PMCID | 2023-Mar | 0.90 | The study is a Phase III randomized trial with a drug intervention (amenamevir) and a primary time-to-event endpoint (time to healing). However, it is not an oncology study; it evaluates a treatment for recurrent herpes labialis, a non-malignant condition. | 待处理 |
| Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.Lancet Infect Dis | PMID 36354034PMC9946839 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.Cancer Sci | PMID 36369901PMC9986093 | 2023-Mar | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.Am J Obstet Gynecol | PMID 36370871无 PMCID | 2023-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.Diabetes Obes Metab | PMID 36433709无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of twice-daily tramadol hydrochloride bilayer sustained-release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double-blind, placebo-controlled, treatment-withdrawal study.Pain Pract | PMID 36478501无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.Clin Colorectal Cancer | PMID 36503738无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.Ann Oncol | PMID 36535565无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.Ann Oncol | PMID 36535566无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.Clin Colorectal Cancer | PMID 36564280无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.Am J Hematol | PMID 36588387无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.Gynecol Oncol | PMID 36608382PMC10023359 | 2023-Mar | 0.85 | The record describes a Phase III randomized trial in ovarian cancer with a time-to-event primary endpoint (PFS), but the intervention is non-drug (lifestyle/diet/exercise). Therefore, it does not meet the 'drug-intervention' criterion. | 待处理 |
| Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).Gynecol Oncol | PMID 36608383无 PMCID | 2023-Mar | 0.85 | The record is an economic evaluation derived from a phase III RCT but does not report direct oncology efficacy outcomes (e.g., survival, progression) required for inclusion in this cohort. | 待处理 |
| Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.Eur J Cancer | PMID 36641898无 PMCID | 2023-Mar | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).Eur J Cancer | PMID 36652891无 PMCID | 2023-Mar | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).J Gynecol Oncol | PMID 36659832PMC9995864 | 2023-Mar | 0.85 | The record is a protocol for a randomized Phase III trial in human endometrial cancer with time-to-event endpoints, but it does not report results and the primary experimental intervention is molecular profile-based radiation therapy, not a specific drug-containing regimen. | 待处理 |
| Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity.Eur J Cancer | PMID 36669426无 PMCID | 2023-Mar | 0.90 | The trial is a Phase III randomized study with time-to-event endpoints (DFS, OS) in oncology. However, the abstract does not specify the chemotherapy agent used in the concurrent chemoradiation arm, and the intervention is primarily described as radiation therapy intensification. Without explicit evidence of a specific drug intervention, the 'drug_intervention' criterion is not met. | 待处理 |
| The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 36702138无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.Lancet Diabetes Endocrinol | PMID 36738751PMC10851109 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Belimumab for the treatment of pediatric patients with lupus nephritis.Expert Opin Biol Ther | PMID 36750049无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.J Urol | PMID 36756959PMC12721655 | 2023-Mar | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.Br J Cancer | PMID 36759721PMC10049995 | 2023-Mar | 0.45 | The record describes a biomarker subgroup analysis of the phase III TRIBE2 randomized trial, reporting OS and PFS outcomes. While it meets the oncology, human, randomized, and phase criteria, and includes relevant survival outcomes, the report is a secondary/subgroup analysis, not the primary or definitive efficacy report of the trial. Eligibility for Kaplan-Meier digitization requires tracing back to the primary trial report, which is not provided here. | 待处理 |
| Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.Lancet Oncol | PMID 36796394无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.BioDrugs | PMID 36802320PMC9971153 | 2023-Mar | 0.95 | The trial is eligible by most criteria (oncology, human, randomized, phase III, drug intervention, original result). However, it is not eligible because the primary endpoint is a biomarker (percentage change in uNTX/uCr), and the only time-to-event secondary endpoint (time to on-study skeletal-related events) is not a standard efficacy endpoint per the adjudication criteria (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier or HR is reported for a primary/secondary time-to-event efficacy endpoint. | 待处理 |
| Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.Lancet Neurol | PMID 36804093无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project.Mult Scler | PMID 36843446无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ravulizumab for the treatment of myasthenia gravis.Expert Opin Biol Ther | PMID 36852670无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.Lancet Oncol | PMID 36858721无 PMCID | 2023-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.HIV Med | PMID 36912173无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.Clin Ther | PMID 36922331无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.RMD Open | PMID 36958766PMC10030648 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.Lancet Rheumatol | PMID 38251609无 PMCID | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study.PLoS Negl Trop Dis | PMID 36888687PMC9994689 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.Alzheimers Res Ther | PMID 36849969PMC9972756 | 2023-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.BMC Res Notes | PMID 36849996PMC9970848 | 2023-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).BMC Med | PMID 36855099PMC9976471 | 2023-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.Lancet | PMID 36774935无 PMCID | 2023-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].Zhonghua Xin Xue Guan Bing Za Zhi | PMID 36789598无 PMCID | 2023-Feb-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.BMC Infect Dis | PMID 36829111PMC9951829 | 2023-Feb-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial.Blood | PMID 36322937PMC10023719 | 2023-Feb-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rucaparib or Physician's Choice in Metastatic Prostate Cancer.N Engl J Med | PMID 36795891PMC10064172 | 2023-Feb-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |